Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1 DOSE ESCALATION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Trial Profile

A PHASE 1 DOSE ESCALATION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs PF-06952229 (Primary) ; Enzalutamide; Letrozole; Palbociclib
  • Indications Adenocarcinoma; Advanced breast cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Oct 2018 Planned End Date changed from 2 Sep 2023 to 24 Aug 2023.
    • 22 Oct 2018 Planned primary completion date changed from 28 Oct 2021 to 19 Oct 2021.
    • 22 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top